NEW YORK — Abbott's fourth-quarter revenue rose 4 percent year over year, the company reported on Thursday, while its diagnostics revenue was down 3 percent. Excluding COVID-19 testing-related sales, ...

The firm's benchtop TruVerus system can now run a total of 26 FDA-cleared assays in three modalities from a single blood collection tube.

NEW YORK — The US Food and Drug Administration has issued warning letters to four direct-to-consumer health testing companies for selling unauthorized blood collection kits for HIV diagnosis.

The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

In addition to pushing cuts off until the beginning of 2027, the bill would update the data collection period used to establish the 2027 lab rates from 2019 to 2025.

The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.

The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...

The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.

The company said that preliminary Q4 revenue was up 39 percent year over year and full-year 2025 revenue increased 35 percent ...

Last week, readers were most interested in a story about the continued lack of clarity around Siemens Healthineers' diagnostics business at JP Morgan.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...